## WELCOME

Form Approved OMB No. 0920-1046 Expiration Date: XX/XX/XXXXXXX

## 2023 Annual National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Survey

The Centers for Disease Control and Prevention (CDC), Division of Cancer Prevention and Control (DCPC) is assessing how DP22-2022 recipients implement the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). This survey asks about your program implementation during program year 1 (PY1), the time period July 1, 2022 through June 30, 2023.

The aims of this data collection are to better understand how you are implementing your BCCEDP; therefore, your feedback is extremely important. You should respond to this survey based upon the work conducted by your program in year 1 only.

If you have any questions about the survey content while completing it, please contact Stephanie Melillo at 770.488.4294 or bcu6@cdc.gov or Justin Uhd at 404.718.5525 or mru7@cdc.gov. If you have technical issues in completing the survey, please contact Information Management Services, Inc. at support@nbccedp.org.

The survey should take approximately 56 minutes to complete in one sitting.

Thank you for your participation.

Click here to download a PDF copy of this survey.

Click here to download a PDF copy of the webinar slides.

Public reporting burden of this collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road, NE, MS D-74, Atlanta, GA 30233. ATTN: PRA (0920-1046).

## INSTRUCTIONS AND DEFINITIONS

#### WHO SHOULD COMPLETE THIS DATA COLLECTION?

The person responsible for the day-to-day management of the program and/or with the most program knowledge should complete this data collection.

#### WHAT TIME PERIOD IS BEING ASSESSED?

We are collecting information about the implementation of your DP22-2022 NBCCEDP, program year 1 (PY1). All responses should reflect implementation of your NBCCEDP in PY1 ONLY, July 1, 2022 – June 30, 2023.

## WHAT DO WE MEAN BY 'YOUR BCCEDP'?

The term 'Your BCCEDP' refers to all those involved in the implementation of your NBCCEDP program/program activities, including you, your consultants and/or contractors, and your partners, regardless of the <u>source of program funds</u>.

## WHAT DO WE MEAN BY 'HEALTH SYSTEM'?

For purposes of this survey, when we use the term 'health system', we mean entities delivering clinical care to a defined patient population including, but not limited to, federally qualified health centers/community health centers (FQHCs/CHCs), other publicly funded entities providing primary care, academic health care centers, health plan clinic networks, other health care networks, and hospitals. Health systems often include multiple primary care clinic sites.

Insurers/health care plans, Medicaid, and Medicare may also be considered health systems given they have an applicant-defined patient population and reimburse for clinical services rendered.

#### WHAT ARE THE STRATEGIES AND ACTIVITIES OF INTEREST?


The NBCCEDP implements a comprehensive and coordinated approach to increase access to breast and cervical cancer screening services for women in partner clinical settings. These strategies include using cancer data and surveillance to identify program-eligible population and inform screening projections, delivering breast and cervical screening and diagnostic services, implementing evidence-based interventions (EBIs) in partner clinics, and conducting program monitoring and evaluation. Detailed descriptions of each of these strategies can be found on the NBCCEDP website: https://www.cdc.gov/cancer/dcpc/pdf/dp22-2022-nbccedp-logic-model-text.pdf.

#### WHAT ARE EVIDENCE-BASED INTERVENTIONS?

Our program considers evidence-based interventions (EBIs) to be those strategies that have been reviewed and recommended by the Community Guide to Preventive Services Task Force (Community Guide). Definition for these strategies (Provider Assessment and Feedback (PAF), Provider Reminders (PR), Reducing Structural Barriers (RSB), Patient (Client) Reminders (CR), Interventions that engage Community Health Workers (CHWs), Small Media (SM), Group Education (GE), One on One Education (OOE) and Reducing out of Pocket Costs (ROPC)) can be found on the Community Guide website: https://www.thecommunityguide.org/topic/cancer.

## WHAT IS PATIENT NAVIGATION?

Patient navigation is a strategy aimed at assisting women who receive screening or diagnostic services in overcoming barriers to complete screening and diagnostic services, and initiate cancer treatment. All women enrolled in the NBCCEDP for clinical services must be assessed to determine if patient navigation services are needed and provided with these services according to CDC guidance (e.g., assessment, education, barrier reduction, follow-up).



The following question will only be asked in program years 2-5.

3. Are you the person who responded to this survey last year?  ① Choose one of the following answers	
Yes No	

# **SECTION 2: PROGRAM MANAGEMENT**

1. Using the following response options: "Did not use", "Used, but not helpful", "Helpful", and "Very helpful," how useful did you find the following technical assistance resources in PY1?

Technical Assistance Resources	Did Not Use	Used, But Not Helpful	Helpful	Very Helpful
New recipient staff orientation materials	0	0	0	0
Measuring Breast, Cervical, and Colorectal Cancer Screening Rates in Health System Clinics: Guidance Document				
Clinic Data Collection Forms	0	0	0	0
NBCCEDP Clinic Data Users' Manual	0			0
CDC NBCCEDP website www.cdc.gov/cancer/nbccedp	0	0	0	0
Screen Out Cancer website www.cdc.gov/screenoutcancer				
Clinic Data Reports in B&CBARS and Tableau	0	0	0	0
Clinic implementation readiness assessment (Clinic IRA) tool				
Evaluation Planning Guidance Document	0	0	0	0
MDE Data Users' Manual (including MDE data dictionaries)				
MDE Feedback Reports	0	0	0	0
CDC NBCCEDP DP22-2022 Program Manual Part 1	0			0
CDC NBCCEDP DP22-2022 Program Manual Part 2 (TBD)	0	0	0	0
Evidence Based Intervention Planning Guides (EPGs)				
Quick Guide to Planning and Implementing Selected Activities to ncrease Breast, Cervical, and Colorectal Cancer Screening	0	0	0	0
State Maps with county level screening rate estimates				
NBCCEDP Evaluation Network	0	0		0

# Question 1, continued

TA provided by Evaluation Team and/or IMS			
TA provided by OFR			
Ask Dr. Miller Newsletter		0	
Success story templates			
Health Equity 1-pager		0	
SMART objective 1-pager			
Strategy 1-pagers		0	
Other TA Resource (please specify one resource or select 'did not use' if you have no other resource to add)			
1A. Other TA Resource (please specify one resource, do not enter 'N/A' or 'N	NONE')		
1A. Other TA Resource (please specify one resource, do not enter 'N/A' or 'N	NONE')		
1A. Other TA Resource (please specify one resource, do not enter 'N/A' or 'N	NONE')		
1A. Other TA Resource (please specify one resource, do not enter 'N/A' or 'N	NONE')		
1A. Other TA Resource (please specify one resource, do not enter 'N/A' or 'N	NONE')		

2. Please list the amount of Federal (do not include BCCEDP funds, which are displayed above the table), State, Tribal, non-profit, university and other funding that supported or supplemented your BCCEDP program in PY1. Please pro-rate funding if needed to associate with PY1, July 1, 2022 – June 30, 2023. Do not include inkind resources.  BCCEDP 1701 award for PY1:					
• Your answer must be an integer between 0 and 99999999. Enter '0' if funding was not received (for any of the options below, including Other).					
Non-BCCEDP Federal Funds	\$	.00			
State	\$	.00			
Tribal	\$	.00.			
Non-profit (e.g. American Cancer Society, LIVESTRONG)	\$	.00			
University (e.g. other grant funds, internal university funds)	\$	.00			
Other funding sources (please specify or enter 0 if no other funding sources)	\$ 1	.00			
2A. Other funding sources (please specify, do not enter 'N/A' or 'NONE')					

# **SECTION 3: PARTNERSHIPS**

Please indicate which of the following CDC funded programs your BCCEDP partnered with during PY1.     Check all that apply				
	Colorectal Cancer Control Program (CRCCP)  Comprehensive Cancer Control Program (CCC) (including State Cancer Coalition)  National Program for Cancer Registries (NPCR)  WISEWOMAN  Million Hearts Program  Diabetes Prevention Program  National Tobacco Control Program  State Physical Activity and Nutrition Program (SPAN)			
	National Immunization Program (NIP)  Other NBCCEDP funded programs  We did not partner with any of these programs			
2. Have you partnered with any state or local COVID Vaccine efforts?  ① Choose one of the following answers  Yes  No				

3. Please indicate the number of partners (up to ten) that helped support your program activities in PY1. Partners can include both those that you fund (e.g., contract) and those that collaborate with your program but are not funded by you to do so.			
Only numbers may be entered in this field. Please enter an integer between 0 and 10.			
	partner(s)		

The following four questions will be asked for each of the partners specified in question #3.

4. What is the name of partner #1.			
	ng (if any) that you provided partner #1.		
	er between 0 and 99999999. Enter '0' if funding was not provided.		

	Did you have a Memorandum of Understanding (MOU) or contract in place with partner #1 in PY1?  Choose one of the following answers
	Choose one of the following answers
0	Yes
0	No
y.	
7.1	Which of the following activities did partner #1 conduct in PY1?
90	Check all that apply
	Conduct implementation readiness assessment
	Improve usability of EHRs
	Provide TA for clinic QI efforts
	Provide TA for EBI implementation
	Collect clinic data
	Evaluation
	CHW activities
	Conduct outreach to program-eligible women
	Conduct outreach to specific populations of focus
	Connect women to needed health (other than breast and cervical cancer screening services), community, and social services
	Other (please specify only if applicable, do not enter 'N/A' or 'NONE'):

SEC	TION 4: HEALTH SYSTEMS CHANGE FOR SCREENING DELIVERY				
Ple	CLIENT ELIGIBILITY CRITERIA  ease describe who was eligible for screening and diagnostic services through your BCCEDP program, based on your program's general eligibility requirements, cluding Federal Poverty Level, age, and insurance status.				
•	1. During PY1, what Federal Poverty Level (FPL) was used to determine eligibility for clients receiving NBCCEDP-funded clinical (screening/diagnostic) services?  ① Choose one of the following answers ② Only numbers may be entered in 'Other % FPL (please specify):' accompanying text field.				
	250% FPL 200% FPL				

2. During PY1, at what age were average risk women eligible for screening in your program?				
(Do not report exceptions for special circumstances, e.g., younger women if symptomatic or higher risk.)				
• Please enter an integer between 18 and 99. If you do not provide the specific testing, enter '99'.				
Minimum age for mammography screening	years			
Minimum age for Pap testing	years			
Minimum age for Pap with HPV co-testing	years			
Minimum age for primary HPV testing	years			
3. During PY1, were under-insured clients eligible to re-	ceive clinical services through your BCCEDP?			
(i.e. under-insured are clients who are insured but cannot af	ford their insurance co-pay or deductible or whose insurance plan does not cover cancer screening.)			
• Choose one of the following answers				
O Yes				
O No				

4. During PY1, what percentage of clients receiving screening and/or navigation services through your BCCEDP program were under-insured?  • Please enter an integer between 0 and 100. If you do not know the percentage, enter 'UNK'.			
Perc	sentage of under-insured women		
	During PY1, which payment reimbursement model best describes how your BCCEDP program paid for screening and diagnostic clinical services?  Check all that apply		
	Our organization provides clinical services directly		
	Fee for service (Provider bills and is reimbursed for services/procedures performed; may be managed internally by the recipient or externally by contractor, third party payer, etc.)		
	Capitated payment (A uniform reimbursement rate per person served is established for a specified group of screening and/or diagnostic services.)		
	Bundled payment (Reimbursement model where rates are established according to tiered case outcomes and are reimbursed retrospectively)		
	Employed/Contracted Service Provider (Recipient uses NBCCEDP funds to employ or contract with service providers for screening and/or diagnostic services; uses other vendor for cytology, radiology, etc.)		
	Other payment model (please specify only if applicable, do not enter 'N/A' or 'NONE'):		

6. In the table below, please enter the number of individual <b>primary care sites</b> that delivered BCCEDP screening/diagnostic services in PY1 according to the type of provider setting. <b>Primary care sites</b> are where patients go to receive day-to-day health care, including cancer screening, from a health care provider. Please provide the total number of individual <b>sites or clinics</b> , not the number of contracts. Do <b>not</b> include specialty clinics. A site/clinic should be categorized in one of the four groups below, do <b>not</b> include a single clinic in more than one category.		
Previous Year Responses: FQHCs - IHS - Hospitals/PCPs - Other -		
• Please enter an integer between 0 and 9999. If no sites of this type participated, enter '0'. If this type of sites, enter 'UNK'.	site participated, but you do not know the number of	
Federally Qualified Health Centers or Community Health Centers	sites	
Indian Health Service (IHS) or other tribal health organization sites or clinics (IHS sites that are also FQHC/CHCs should be classified in this category)	sites	
Hospitals, health care systems, or any primary care provider (PCP) sites or clinics, not including FQHCs	sites	
Other primary care sites (please specify below, enter 0 if no other sites)	sites	

The following three questions will only be displayed for state awardees.

7. Congress passed the Breast and Cervical Cancer Prevention and Treatment Act of 2000 (Medicaid Treatment Act) and we would like to assess its current status in each state. Is the Medicaid Treatment Act currently in place in your state?
♣ Choose one of the following answers
O Yes
O No
8. Who is eligible in your state to receive this special Medicaid coverage for breast or cervical cancer treatment in your state?  ① Check all that apply
Only women enrolled in your BCCEDP who are diagnosed with cancer or a precancerous condition
Any woman diagnosed with cancer or a precancerous condition at a screening site that provides BCCEDP screening services
Any woman diagnosed with cancer or a precancerous condition who would be eligible for the BCCEDP but may not have been screened with Federal funds
Other (please specify only if applicable, do not enter 'N/A' or 'NONE'):


<ol> <li>Do you have a process to ensure women diagnosed with cancer thr coverage through Medicaid Treatment Act?</li> <li>Choose one of the following answers</li> </ol>	rough your BCCEDP have access to cancer treatment if your st	ate/jurisdiction does not offer
Yes (please describe only if applicable, do not enter 'N/A' or 'NONE'):  No		

# SECTION 5: EBI IMPLEMENTATION FOR HEALTH SYSTEMS CHANGE A. EBI IMPLEMENTATION 1. During PY1, who provided implementation support (i.e., technical assistance) for EBI-related activities to your partner health systems and/or clinics? Check all that apply BCCEDP staff members Partner organization(s) Did not provide 2. How did you deliver implementation support/TA for EBI-related activities to clinics? Check all that apply Practice facilitation Peer learning (e.g., project ECHO) In person or virtual site visits Phone/conference calls Webinars Trainings, classes, seminars, professional conferences Infographics, publications or reports Other (please specify only if applicable, do not enter 'N/A' or 'NONE'):

3. Did you implement any of the following activities to identify, reach out to or connect program-eligible women to needed health, community and social services in PY1?			
0	Check all that apply		
	Identify program-eligible women using state or local data		
	Reach out to program-eligible women in need of breast or cervical cancer screening and follow-up		
	Partner with organizations to link program-eligible women to needed health (other than breast and cervical cancer screening services), community, and social services		
	Connect program-eligible women to needed health (other than breast and cervical cancer screening services), community and social services		
	No		
	Did you implement any of the following activities to identify, reach out to or connect women in your population(s) of focus to needed health, community and social ervices in PY1?		
0	Check all that apply		
	Identify population(s) of focus using state or local data		
	Partner with organizations that show expertise in or have access to population(s) of focus		
	Reach out to women in your population(s) of focus in need of breast or cervical cancer screening and follow-up services		
	Partner with organizations to link population(s) of focus to needed health (other than breast and cervical cancer screening services), community, and social services		
	Connect population of focus to needed health (other than breast and cervical cancer screening services), community and social services		
	No		

ider	Vere community-based patient navigators or other community-based workers (e.g. health educator, community health worker, community nurse, promotora) used to ntify, reach out to or connect your population(s) of focus to needed health, community, and social services during PY1?
0	Yes No
	n PY1, did you track women reached through these activities through screening completion?
0	Choose one of the following answers  Yes
0	No

7. In PY1, how many women were reached through these activities by your B were contacted. A woman contacted separately for both breast and cervical screen	BCCEDP? (please report the number of women reached, regardless of the number of times they ning should only be counted once)
• Please enter an integer between 0 and 50000. If you do not know the nu	umber of women, enter 'UNK'. Second response must be less than or equal to the first.
How many women were reached through these activities?	women
Among those women reached through these activities, how many of them completed breast and/or cervical cancer screening?	women
8. In PY1, how did you confirm screening completion for women reached thro	ough these activities?
⊕ Check all that apply	
Based on medical records	
Based on woman's self-report	
Billing System	
Linkage with MDEs	
We did not confirm screening completion	



The following three questions will be asked for each staff member specified in question 1.

2. What is the position of staff person #1 deployed to assist on the COVID-19 response during PY1.
3. What percentage of FTE time did staff person #1 spend deployed (e.g., 50%, 100%)?  • Please enter an integer between 1 and 100. If you do not know the percentage, enter 'UNK'.
Percentage of FTE time deployed
4. What was the length of time staff person #1 was deployed in weeks?  • Please enter an integer between 1 and 52. If you do not know the number, enter 'UNK'.
Length of time deployed in weeks

32. Did your BCCEDP program experience staffing shortages due to COVID-19 related reasons (other than deployment) during PY1?
○ Yes ○ No
33. How many of your provider sites that <b>deliver BCCEDP screening and diagnostic services</b> experienced staffing shortages that limited their capacity to provide
screening services for some amount of time due to COVID-19 during PY1?  Choose one of the following answers
Some All
O Do not know None
34. Approximately what percentage of your provider sites that deliver BCCEDP screening and diagnostic services suspended (i.e., temporarily stopped) or reduced breast and/or cervical cancer screening for some amount of time due to COVID-19 during PY1 although the clinic or provider practice remained open?  1 Please enter an integer between 0 and 100. If you do not know the percentage, enter 'UNK'.
Percentage of provider sites

35. Approximately what percentage of your partner clinics that implement evidence-based interventions (EBIs) did your BCCEDP program temporarily stop working with during PY1 (e.g., temporarily stopped providing TA to these clinics) due to COVID-19?
100. If you do not know the percentage, enter 'UNK'.
Percentage of partner clinics %
36. During PY1, did your BCCEDP provide assistance to clinics to screen women who had missed their appointments and/or delayed routine clinical care due to COVID-19?  Choose one of the following answers
Yes (please describe; do not enter 'N/A' or 'NONE'):  No
37. Are there other ways that your BCCEDP program was affected by COVID-19 in PY1?  Choose one of the following answers
Yes (please describe; do not enter 'N/A' or 'NONE'):  No